(Q24244832)

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

When can odds ratios mislead?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

Current and future trends in immunization against meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

Assessing vaccine efficacy in the field. Further observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

The 1990 meningococcal meningitis epidemic of Sarh (Chad): how useful was an earlier mass vaccination?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

A comparison between participants and non-participants in a primary preventive trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Influenza A and meningococcal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Quadrivalent meningococcal conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Meningitis outbreaks and vaccination strategy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Timely detection of meningococcal meningitis epidemics in Africa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Beyond randomised versus observational studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Effect of group-A meningococcal vaccine in army recruits in Finland

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Impairment of the immune response to vaccination after acute malaria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Control of meningococcal infection in the African meningitis belt by selective vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Control of epidemic meningococcal meningitis by mass vaccination.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Shift in the age-distribution of meningococcal disease as predictor of an epidemic?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Meningococcal carriage, meningococcal disease and vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Meningitis A conjugate vaccine comes on stream

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Enhancement of the immune response to meningococcal polysaccharide vaccine in a malaria endemic area by administration of chloroquine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Meningococcal Disease: Still with Us

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Group A meningococcal disease in the U.S. Pacific Northwest: epidemiology, clinical features, and effect of a vaccination control program

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Control of epidemic group A meningococcal meningitis in Nepal

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Detection of meningitis epidemics in Africa: a population-based analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Exact estimates for a rate ratio

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

An exact method for meta-analysis of case-control and follow-up studies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

An outbreak of meningococcal disease in Auckland, New Zealand.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Vaccines for prevention of meningococcal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Household crowding a major risk factor for epidemic meningococcal disease in Auckland children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Infectious disease. An ill wind, bringing meningitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Prevention of secondary cases of meningococcal disease in household contacts by vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Quantitative Determination of the Human Immune Response to Immunization with Meningococcal Vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021

Features of a large epidemic of group A meningococcal meningitis in Khartoum, Sudan in 1988.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001093.PUB2

7 January 2021